Tema Etfs LLC Buys New Shares in Terns Pharmaceuticals, Inc. $TERN

Tema Etfs LLC purchased a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,244 shares of the company’s stock, valued at approximately $414,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after buying an additional 770 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Terns Pharmaceuticals in the second quarter valued at about $41,000. Canada Pension Plan Investment Board bought a new stake in Terns Pharmaceuticals during the second quarter worth about $46,000. Dynamic Technology Lab Private Ltd bought a new stake in Terns Pharmaceuticals during the first quarter worth about $51,000. Finally, Velan Capital Investment Management LP boosted its position in Terns Pharmaceuticals by 17.6% during the second quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock valued at $75,000 after purchasing an additional 3,000 shares during the last quarter. 98.26% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on TERN shares. TD Cowen lowered Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 price target on the stock. in a research report on Thursday, March 26th. UBS Group raised Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Mizuho cut shares of Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 27th. Leerink Partners started coverage on shares of Terns Pharmaceuticals in a report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price on the stock. Finally, Truist Financial lowered shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $56.00 to $53.00 in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $56.30.

Insider Activity

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the sale, the chief executive officer owned 138,976 shares of the company’s stock, valued at $5,294,985.60. The trade was a 33.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Emil Kuriakose sold 942 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the transaction, the insider owned 105,673 shares in the company, valued at approximately $5,574,250.75. The trade was a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 170,196 shares of company stock worth $6,568,912 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Terns Pharmaceuticals Trading Down 0.1%

NASDAQ:TERN opened at $52.72 on Friday. The stock has a 50 day simple moving average of $42.59 and a 200 day simple moving average of $30.32. The stock has a market cap of $6.08 billion, a P/E ratio of -51.18 and a beta of -0.37. Terns Pharmaceuticals, Inc. has a 1-year low of $1.87 and a 1-year high of $53.19.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Thursday, April 2nd. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. As a group, sell-side analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

Terns Pharmaceuticals Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.